MGTX Stock Forecast: MeiraGTx Holdings Plc Price Predictions for 2026-2027

Last close, 20 Nov 2026
$7.98
−1.97% on the day

The 8 Wall Street analysts covering MeiraGTx Holdings Plc hold a median 12-month price target of $24 — +194.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 70 of 100 as at 21 Nov 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$779.9M
Ticker Nerd rank
70/ 100
Median analyst target
$24
Analysts covering
8
Revenue$321.4M+8608.6% y/y
Operating income$244.4M
Net income$160.7M
Free cash flow−$62.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−13.1%
1M
−20.0%
YTD
+0.4%
1Y
+7.4%
From 52W high
−46.7%
From 52W low
+14.2%
$7
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores MeiraGTx Holdings Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
70/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
99
Value
95
Quality
89
Revisions
64
Momentum
58
Volatility
57
Issuance
11
Accruals
7

Growth (99): Sales and profits are climbing, and climbing faster than before.

Accruals (7): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MGTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MGTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Jan 26Apr 26Jul 26Oct 26MGTXHigh $50Median $24Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7
Buy
1
Hold
0
Sell
$16
Low
$24
Median
$50
High

The green dot is the last close — the median target sits +194.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Sept 2026Goldman SachsInitiatesNeutral$16
14 Aug 2026RBC CapitalMaintainsOutperform$26 → $27
8 July 2026HC Wainwright & Co.ReiteratesBuy$20
8 July 2026RBC CapitalMaintainsOutperform$25 → $26
15 May 2026RBC CapitalMaintainsOutperform—
22 Apr 2026Piper SandlerMaintainsOverweight—
17 Apr 2026RBC CapitalMaintainsOutperform—
1 Apr 2026Evercore ISI GroupMaintainsOutperform—
27 Mar 2026B of A SecuritiesMaintainsBuy—
27 Mar 2026Chardan CapitalMaintainsBuy—
27 Mar 2026Piper SandlerMaintainsOverweight—
24 Nov 2025HC Wainwright & Co.InitiatesBuy—
14 Nov 2025Chardan CapitalMaintainsBuy—
14 Nov 2025RBC CapitalMaintainsOutperform—
11 Nov 2025Chardan CapitalMaintainsBuy—
11 Nov 2025Piper SandlerMaintainsOverweight—
21 Oct 2025Raymond JamesInitiatesStrong Buy—
15 Aug 2025Chardan CapitalMaintainsBuy—
14 May 2025Chardan CapitalMaintainsBuy—
17 Mar 2025RBC CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MGTX.

Market Radar

This page is one stock. Monday covers all of them.

MGTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MGTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, MeiraGTx Holdings Plc returned +7.4% against +6.9% for the S&P 500, dividends included.

MGTX vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Jan 26Apr 26Jul 26Oct 26MGTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MGTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
0.0%
Analysts raising
2
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
9.2×

Cheaper than 76% of US stocks

Price / sales
1.9×

Cheaper than 49% of US stocks

Price / book
3.6×

Cheaper than 26% of US stocks

EV / EBITDA
3.8×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
97.8%

Higher than 99% of US stocks

Operating margin
44.8%

Higher than 95% of US stocks

Net margin
19.5%

Higher than 81% of US stocks

Returns & dividend
Return on equity
89.5%

Higher than 96% of US stocks

Return on assets
37.5%

Higher than 99% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • MeiraGTx Holdings Plc has a market value of $779.9M and an enterprise value of $729.2M.

  • Revenue in the twelve months to 30 June 2026: $397.5M. The latest quarter grew 8608.6% year on year.

  • Net income over the same four quarters: $78.9M, a 19.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$14.2M.

  • Shares outstanding: 94.2M.

  • Trailing P/E: 9.2×.

  • MeiraGTx Holdings Plc employs 386 people — $1.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

MGTX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MGTXMeiraGTx Holdings Plc$779.9M70
MTRIMentari Therapeutics, Inc.$776.4M24
VSTMVerastem, Inc.$769.1M39
BBTXBambusa Therapeutics, Inc.$796.2M0
ORICOric Pharmaceuticals, Inc.$761.9M53
ODTXOdyssey Therapeutics, Inc.$800.1M1
SNDXSyndax Pharmaceuticals, Inc.$757.9M58

Take a look at MGTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own MeiraGTx Holdings Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about MGTX

What is the MGTX stock price forecast for 2026-2027?

The 8 Wall Street analysts covering MeiraGTx Holdings Plc have a median 12-month price target of $24, with estimates ranging from $16 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MGTX stock a buy right now?

Of the 8 analysts covering MeiraGTx Holdings Plc, 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MeiraGTx Holdings Plc 70 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MGTX?

As at 21 Nov 2026, MeiraGTx Holdings Plc ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).

Will MGTX stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +194.5% from the last close, and Ticker Nerd's factor model ranks MeiraGTx Holdings Plc 70 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MGTX stock forecast for 2030?

No analyst covering MeiraGTx Holdings Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MGTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $50 over the next 12 months.

How has MGTX stock performed over the past year?

MeiraGTx Holdings Plc returned +7.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MeiraGTx Holdings Plc do?

MeiraGTx Holdings plc is a clinical-stage genetic medicines company focused on developing gene and cell therapies for serious inherited and acquired diseases. MeiraGTx Holdings plc uses a vertically integrated model that combines discovery, development, and manufacturing capabilities to support its genetic medicine programs.

Company

About MeiraGTx Holdings Plc.

MeiraGTx Holdings plc is a clinical-stage genetic medicines company focused on developing gene and cell therapies for serious inherited and acquired diseases. MeiraGTx Holdings plc uses a vertically integrated model that combines discovery, development, and manufacturing capabilities to support its genetic medicine programs. Its current pipeline targets conditions in the eye, salivary gland, and central nervous system, including retinal disorders, radiation-induced xerostomia, and Parkinson’s disease. The company’s work centers on local delivery of small doses designed to produce disease-modifying effects in areas of high unmet medical need. MeiraGTx Holdings plc operates as part of the biotechnology and health technology market, where it contributes to the advancement of precision therapies built around genetic intervention.

CEO Dr. Alexandria Forbes Ph.D. · 386 employees · United States · https://www.meiragtx.com